Status:
TERMINATED
Positron Emission Tomography - Computed Tomography (PET-CT) Cetuximab Project
Lead Sponsor:
Universitaire Ziekenhuizen KU Leuven
Conditions:
Metastatic Colorectal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Molecular imaging with positron emission tomography (PET) using \[18F\] fluorodeoxyglucose (FDG) has been suggested as an early, sensitive marker of tumour response to anticancer drugs by monitoring t...
Eligibility Criteria
Inclusion
- Histologically or cytologically proven colorectal cancer
- Unresectable stage IV disease
- K-Ras wild type tumour
- Patients scheduled to undergo chemotherapy with irinotecan and cetuximab
Exclusion
- Prior abdominal/pelvic radiotherapy, surgery or chemotherapy within 3 months prior to inclusion in the study
- Poorly controlled diabetes
- Concomitant serious illness, such as uncontrolled angina pectoris, myocardial infarction, heart failure, uncontrolled hypertension, infection
- Symptomatic brain metastases
- Pregnancy or participants of reproductive potential who are sexually active and not willing/able to use medically appropriate contraception
Key Trial Info
Start Date :
January 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT00828620
Start Date
January 1 2009
End Date
June 1 2012
Last Update
August 10 2012
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
ZNA Middelheim
Antwerp, Belgium
2
AZ Groeninge
Kortrijk, Belgium
3
UZLeuven
Leuven, Belgium, 3000
4
H Hart Roeselare Campus menen
Menen, Belgium